Pacira BioSciences, Inc. (PCRX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Pacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 pacira2014amendedandrestat.htm EX-10.1 Document Exhibit 10.1 PACIRA BIOSCIENCES, INC. AMENDED AND RESTATED 2014 EMPLOYEE STOCK PURCHASE PLAN (As approved by stockholders on June 9, 2026) SECTION 1. PURPOSE The purposes of the Amended and Restated 2014 Employee Stock Pur
How this was made
The 30-second read
Why it matters
The newest concrete disclosure is the ESPP amendment/restatement (including a maximum of 1,800,000 shares under the plan) alongside director/officer election/appointment details; these are typically not immediate fundamental drivers.
Market read
Primarily governance/employee equity compensation mechanics; likely limited trading impact unless the director/officer changes are material.
What to watch
Traders should check the full 8-K for specifics on who departed/was appointed and whether any compensation terms imply retention or restructuring beyond the ESPP text.
Background
This SEC 8-K covers Item 5.02/5.07 and includes the amended and restated 2014 Employee Stock Purchase Plan approved by stockholders on June 9, 2026.
Ticker impact
Pacira BioSciences files an 8-K detailing board/officer changes and approval of an amended and restated 2014 employee stock purchase plan.
Likely low near-term impact; any reaction would be sentiment/compensation-structure related rather than fundamentals.
The disclosed items are an ESPP amendment/restatement and related director/officer matters, not guidance, trial results, or a material transaction.
Market effects
Minimal; ESPP/board-compensation changes generally do not alter sector fundamentals.
None indicated.
None indicated.
Counterpoint
If the director/officer changes signal a strategic pivot, the market could re-rate the stock despite the ESPP being a secondary disclosure.
Key entities
- issuerPacira BioSciences, Inc.
Company filing the 8-K; subject of the director/officer and ESPP plan disclosures.
- compensation_planAmended and Restated 2014 Employee Stock Purchase Plan
Stockholder-approved ESPP amendment/restatement with plan administration and share authorization details.
